公开(公告)号：US20230212231A1

公开(公告)日：2023-07-06

申请号：US17927804

申请日：2021-05-26

Applicant: Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Baylor Research Institute ,  Assistance Publique - Hopitaux de Paris (APHP) ,  Universite Paris Est Creteil Val de Marne

Inventor： Yves LEVY ,  Gérard ZURAWSKI ,  Sandra ZURAWSKI ,  Christine LACABARATZ ,  Sylvain CARDINAUD ,  Mathieu SURENAUD

IPC: C07K14/005 ,  C07K16/28 ,  A61P31/14

CPC classification number: C07K14/005 ,  C07K16/2878 ,  C07K16/2851 ,  A61P31/14 ,  C12N2770/20022 ,  C07K2319/74 ,  C12N2770/20034 ,  A61K39/00

Abstract: The present disclosure provides polypeptides derived from SARS-CoV-2 which have therapeutic use. One such polypeptide is a polypeptide, referred to as “Npep2,” is derived from the SARS-CoV-2 protein N and has at least 50 consecutive amino acids of the amino acid sequence having at least 90% identity with the amino acid sequence that ranges from the residue at position 276 to the residue at position 411 of SEQ ID NO:2. Further described are conjugates wherein a heterologous polypeptide is conjugated or fused to Npep2. The present disclosure further provides vaccines employing the polypeptides, polynucleotides encoding the polypeptides, and methods of vaccinating subjects against SARS-CoV-2 by administering a therapeutically effective amount of one or more of the polypeptides.

公开(公告)号：US20210299224A1

公开(公告)日：2021-09-30

申请号：US17301123

申请日：2021-03-25

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Hyemee JOO ,  Gerard ZURAWSKI

IPC: A61K38/20 ,  C07K14/54 ,  A61K39/00 ,  C07K16/28

Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.

公开(公告)号：US10993990B2

公开(公告)日：2021-05-04

申请号：US15311572

申请日：2015-05-15

Applicant: Baylor Research Institute

Inventor： SangKon Oh ,  Sandra Zurawski ,  Hyemee Joo ,  Gerard Zurawski

IPC: A61K38/20 ,  C07K14/54 ,  A61K39/00 ,  C07K16/28

Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.

公开(公告)号：US10980869B2

公开(公告)日：2021-04-20

申请号：US15703685

申请日：2017-09-13

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Gerard Zurawski ,  Jacques F. Banchereau ,  Anne-Laure Flamar ,  Peter Klucar ,  Keiko Akagawa ,  Sandra Zurawski ,  SangKon Oh

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C07K14/435

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US20200345813A1

公开(公告)日：2020-11-05

申请号：US16947126

申请日：2020-07-20

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Maria Virginia Pascual

IPC: A61K38/20 ,  C07K16/24 ,  A61K38/17 ,  C07K14/545 ,  G01N33/68

Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.

公开(公告)号：US20200323466A1

公开(公告)日：2020-10-15

申请号：US16946536

申请日：2020-06-25

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： M. Yair LEVY ,  Houston HOLMES

IPC: A61B5/11 ,  A61B5/00 ,  G16H20/10 ,  G16H40/63 ,  G16H10/60 ,  G16H50/20

Abstract: A system for improving the treatment of a patient's disease. A patient is fitted with a wireless motion capture device. A computer system receives the captured motion data other patient metric information and compares same to stored data sets. The stored data sets may comprise other motion data and/or metric data from the patient being examined, or captured data from other patients. The stored data sets can also be tagged with, or otherwise associated with, one or more treatment protocols. A model can be formed with respect to the patient's captured motion and other metric information. A probable treatment of the diseases, effectiveness of the patient's treatment regimen, and progression of the disease itself can be ascertained from the comparison.

公开(公告)号：US10519506B2

公开(公告)日：2019-12-31

申请号：US14367827

申请日：2012-12-21

Applicant: Baylor Research Institute

Inventor： Ajay Goel ,  C. Richard Boland ,  Keun Hur

IPC: C12Q1/68 ,  C12Q1/6886

Abstract: The present invention includes methods and biomarkers for diagnosing or detecting colorectal cancer metastasis in a human subject by comparing the Alu repeat methylation level in the biological sample to an Alu repeat methylation control level from a normal non-cancerous sample from the human subject, wherein a decrease in the Alu repeat methylation level is indicative of colorectal cancer and colorectal cancer metastasis. The invention also includes methods and biomarkers for diagnosing or detecting colorectal cancer (CRC) metastasis in a human subject by determining a level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample from the one or more biological samples; and comparing the level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample with the level of expression of let-7i, miR-10b, miR-320a, and miR-221 from normal colorectal tissue, wherein high expression of at least on of let-7i or miR-320a is indicative of a good prognosis for the CRC, while the low expression of at least one of miR-10b or miR-221 is indicative of a good prognosis for the CRC or CRC metastasis.

公开(公告)号：US20190316207A1

公开(公告)日：2019-10-17

申请号：US16372747

申请日：2019-04-02

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay Goel ,  Lucia Perez-Carbonell ,  C. Richard Boland

IPC: C12Q1/6886 ,  G16H10/60 ,  C12N15/113 ,  A61K31/513 ,  G16H40/63

Abstract: Embodiments provide methods and compositions related to determining treatments for colorectal cancer patients by detection and analysis of the expression level of miRNA such as miR-320e in the patients.

公开(公告)号：US20190038585A1

公开(公告)日：2019-02-07

申请号：US16100771

申请日：2018-08-10

Applicant: Baylor Research Institute

Inventor： Charles R. ROE

IPC: A61K31/20 ,  A61K31/19 ,  A61K31/23 ,  A61K31/194

Abstract: A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients has been found which comprises a seven-carbon fatty acid chain, wherein the seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or carnitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein the compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.

公开(公告)号：US10023841B2

公开(公告)日：2018-07-17

申请号：US14719968

申请日：2015-05-22

Applicant: Baylor Research Institute

Inventor： Anna Karolina Palucka ,  Jacques F Banchereau ,  Lee Roberts

IPC: A61K39/00 ,  A61K35/15 ,  C12N5/0784 ,  A61K45/06 ,  A61K38/20 ,  A61K31/337 ,  A61K31/675 ,  A61K31/704

Abstract: Disclosed are compositions and methods for treatment of breast cancer. Disclosed methods and compositions include dendritic cells loaded with cyclin B1 and WT-1 peptide antigens for immunotherapy. These dendritic cell vaccines are administered alone or in combination with other cancer therapies to improve outcomes. Disclosed methods also involve the use of therapeutic agents, such as anakinra, that block the IL-1 inflammation pathway. These agents are used in combination with chemotherapy and/or immunotherapy in treating breast cancer.